U.S. Markets close in 1 hr 31 mins
  • S&P 500

    3,952.05
    -11.89 (-0.30%)
     
  • Dow 30

    33,808.42
    -41.04 (-0.12%)
     
  • Nasdaq

    10,976.28
    -73.22 (-0.66%)
     
  • Russell 2000

    1,840.79
    +9.83 (+0.54%)
     
  • Crude Oil

    78.21
    +0.97 (+1.26%)
     
  • Gold

    1,766.00
    +10.70 (+0.61%)
     
  • Silver

    21.47
    +0.34 (+1.63%)
     
  • EUR/USD

    1.0338
    -0.0006 (-0.06%)
     
  • 10-Yr Bond

    3.7520
    +0.0490 (+1.32%)
     
  • GBP/USD

    1.1953
    -0.0012 (-0.10%)
     
  • USD/JPY

    138.5580
    -0.3430 (-0.25%)
     
  • BTC-USD

    16,434.33
    +248.38 (+1.53%)
     
  • CMC Crypto 200

    388.43
    -0.30 (-0.08%)
     
  • FTSE 100

    7,512.00
    +37.98 (+0.51%)
     
  • Nikkei 225

    28,027.84
    -134.99 (-0.48%)
     

Biogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks Game

Biogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks Game

Cambridge, Massachusetts-based biotech Biogen and Japanese drug maker Eisai reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial. The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo. This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic.